Published studies and evidence support DoseMeRx achieving therapeutic doses of important medications to streamline operations, reduce adverse events, and save costs.
DoseMeRx has demonstrated clear clinical and operational benefits in independent peer-reviewed studies.
1
In patients receiving vancomycin with piperacillin-tazobactam, model-informed precision dosing with DoseMeRx was associated with lower AKI incidence and improved target attainment over first-order AUC calculations.
2
A 500-bed hospital switching from trough to Bayesian AUC-guided monitoring with DoseMeRx saw lower AKI rates, fewer serum samples, and cost savings up to $369,000 USD per 300 vancomycin patients.
3
DoseMeRx increases the proportion of vancomycin patients achieving target AUC24 and the percentage of time in therapeutic range.
4
In a retrospective study, one-concentration Bayesian AUC24 estimates showed strong agreement with two-concentration estimates in patients with obesity, supporting the use of a single concentration in this population.
5
In children with cystic fibrosis receiving IV tobramycin, Bayesian forecasting reduced the number of blood draws needed and improved AUC target attainment compared with log-linear regression, with comparable clinical outcomes between groups.
6
Using Bayesian estimation from a single trough concentration, DoseMeRx identified vancomycin exposure associated with AKI risk in patients with MRSA bacteremia, outperforming trough levels alone as a predictor of nephrotoxicity.
7
Using DoseMeRx, Bayesian forecasting reliably predicted tobramycin concentrations in children with cystic fibrosis, with consistent dose recommendations whether one or two concentrations were used.
8
Bayesian forecasting with DoseMe reliably predicted tobramycin exposure in patients with cystic fibrosis, showing low bias and consistent dose recommendations.
9
Cyclosporine treatment for patients with autoimmune diseases showed improved therapeutic range attainment and number of days within target range with the use of DoseMeRx.
DoseMeRx and our customers are continuously working on scientific poster presentations that are presented at conferences around the country.
P1
We compared therapeutic range attainment across five hospitals using vancomycin trough-based dosing versus five hospitals using Bayesian-supported AUC24-based dosing. DoseMeRx enabled significantly higher target attainment with fewer drug concentrations and lower mean doses, suggesting reduced AKI risk and avoiding added lab cost.
DoseMe is bringing together clinical guidance and precision dosing
Firstline puts your institution’s best practices where decisions are made.
Clinically validated models across infectious disease, oncology, transplant, and more.
HIPAA Privacy Statement | Privacy policy | DoseMe & the GDPR | Copyright © 2012 - 2026 DoseMe Pty Ltd. All Rights Reserved.
DoseMe® is a registered trademark of DoseMe Pty Ltd. DoseMeRx℠ and DoseMe℞℠ are service marks of DoseMe LLC.